Ari Grinspan, MD, is an Assistant Professor in the Department of Medicine, Division of Gastroenterology and the Director of the GI Microbial Therapeutics. He received his medical degree from the Albert Einstein College of Medicine in New York and completed his Internal Medicine training at New York-Presbyterian Hospital. He completed his fellowship in Gastroenterology at Mount Sinai Medical Center, where he remains as full-time faculty.
Dr. Grinspan pioneered the Fecal Microbiota Transplant (FMT) program to treat recurrent and refractory Clostridium difficile infection at Mount Sinai, which has developed into a referral center for the tri-state area. His research focuses on exploring the mechanism and clinical utility of FMT in Clostridium difficile infection and Inflammatory Bowel Disease.
For more information on FMT, please read Dr. Grinspan's articles: Guest commentary: The exciting future of fecal microbiota transplant and Fecal Microbiota Transplantation for Inflammatory Bowel Disease,
Certifications
Gastroenterology
Clinical Focus
- Acid Reflux / Heartburn
- Antibiotic-Associated Colitis-C Difficile
- Blood in Stool
- Colon Polyps
- Colorectal Cancer
- Constipation
- Crohn's Disease
- Diarrhea
- Dyspepsia
- Gastritis
- Gastroenterology
- Hemorrhoids
- Inflammatory Bowel Disease
- Iron-Deficiency Anemia
- Irritable Bowel Syndrome
- Nausea and Vomiting
- Peptic Ulcer
- Stomach Pain
- Ulcerative Colitis
Education
MD, Albert Einstein College of Medicine
Residency, Internal Medicine, New York Presbyterian - Weill Cornell Medical Center
Fellowship, Gastroenterology, The Mount Sinai Hospital
-
2013
Chief GI Fellow -
2011
Daniel M. Libby MD Program Directors Award -
2010
Assistant Chief Resident -
2008
Alpha Omega Alpha -
2004
Phi Beta Kappa
Fecal Microbiota Transplantation (FMT)
Dr. Grinspan has pioneered the Fecal Microbiota Transplantation (FMT) program at Mount Sinai to treat recurrent and refractory Clostridium difficile infection.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Grinspan did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.